Posts filtered by tags: CRISPR Therapeutics[x]


 

Vertex Continues Plan to Diversify, Strikes a $70M Pact With Kymera

Vertex Pharmaceuticals is best known for its cystic fibrosis franchise. But over the past several years Vertex has been making inroads elsewhere, and a deal it is announcing this morning continues that strategy.Vertex (NASDAQ: VRTX), of Boston, will pay privately held startup Kymera Therapeutics $70 million to form an alliance to develop a group of drugs for “serious specialty diseases.” Vertex won’t say which ones, but beyond cystic fibrosis (CF), where it has three FDA-approved drugs that gen...
Tags: Deals, Startups, Boston, Trends, Vc, Fda, GlaxoSmithKline, Biotech, Pain, Cystic Fibrosis, Life Sciences, CRISPR Therapeutics, Vertex, Merck KGaA, Hepatitis C, Vertex Pharmaceuticals




Up to $818 million deal between J&J and Locus Biosciences points to a new path for CRISPR therapies

The up to $818 million deal between Locus Biosciences and Janssen Pharmaceuticals (a division of Johnson & Johnson) that was announced yesterday points toward a new path for CRISPR gene editing technologies and (potentially) the whole field of microbiome-targeted therapies. Based in Research Triangle Park, N.C., Locus is commercializing research initially developed by scientists at North Carolina State University that focused on Cas3 proteins, which devour DNA Pac-Man-style, rather than edit it ...
Tags: TC, Science, Biology, Los Angeles, Tech, Genetics, Tencent, Food And Drug Administration, Disease, North Carolina, Infection, Genetic Engineering, Crispr, Executive, Biotechnology, University Of Southern California


Bio Roundup: Alzheimer’s Puzzle, ESMO Assessed, Drug Prices & More

In the biotech investment and research communities this week, much of the attention was turned to Europe.Munich, Germany, hosted the annual conference of the European Society for Medical Oncology, where cancer drug developers unveiled the latest clinical data for experimental immunotherapies and drugs that treat the disease based on a tumor’s genetic signature. Also this week, the Clinical Trials on Alzheimer’s Disease conference took place in Barcelona, Spain. As with another Alzheimer’s meeti...
Tags: Startups, Drugs, Cancer, Trends, Investing, Alzheimer's Disease, Astrazeneca, Medicare, Fda, National, Pfizer, Abbvie, Biotech, Bain Capital, Stanford University, Cystic Fibrosis


DNA editing on-the-cheap is the promise of Synthego, which just raised $110 million from Peter Thiel and other investors

Synthego, a Silicon Valley genome-engineering startup founded by former SpaceX engineers, sells ready-to-use kits that let people experiment with the cutting-edge gene-editing tool Crispr. On Tuesday, Synthego received $110 million from Peter Thiel's Founders Fund and two other Silicon Valley venture firms, bringing the company's total funding to $160 million. Crispr holds massive promise for a field known as gene therapy, which involves modifying someone's DNA to treat a genetic disease. Synt...
Tags: Spacex, Stanford, US, Trends, European Union, Peter Thiel, Silicon Valley, GlaxoSmithKline, Berkeley, UC Berkeley, University Of California, Mayo Clinic, Crispr, Menlo Ventures, UnitedHealth Group, University of California at Berkeley


A Peter Thiel-backed startup led by former SpaceX engineers just raised $110 million to make editing your DNA 'as accessible as vaccines'

A Silicon Valley genome engineering startup founded by former SpaceX engineers called Synthego sells ready-to-use kits that let people experiment with the cutting-edge gene editing tool CRISPR. On Tuesday, Synthego received $110 million from Peter Thiel's Founders Fund and two other Silicon Valley venture firms — bringing the company's total funding to $160 million. CRISPR holds massive promise for a field known as gene therapy, which involves modifying someone's DNA to treat a genetic disease...
Tags: Spacex, Stanford, US, Trends, European Union, Peter Thiel, Silicon Valley, GlaxoSmithKline, Berkeley, UC Berkeley, University Of California, Mayo Clinic, Crispr, Menlo Ventures, UnitedHealth Group, University of California at Berkeley


Bio Roundup: BIO Diversity, Allogene IPO, CRISPR In Utero & More

Nearly four years after in a $265 million IPO, cancer immunotherapy remains a hot ticket. Like Juno, Allogene Therapeutics just pulled in a massive IPO haul, nearly $300 million. And like Juno, Allogene is working with a live immune-cell treatment called CAR-T, but it is harvesting cells from anonymous donors instead of from the same patients slated to receive the therapy, which is Juno’s method.While certain biotech subsectors have no problem raising cash, the industry writ large is having t...
Tags: Ipo, Study, Funding, Failure, Trends, Diversity, Fail, Cybersecurity, Vc, Democrats, President, Venture Capital, Medicare, Fda, National, Sma


CRISPR, ViaCyte Team Up to Develop Stem Cell-Based Diabetes Therapy

ViaCyte’s attempts to develop a stem cell therapy for diabetes have been stymied by the immune system, which recognizes the implanted cells as foreign. Meanwhile, CRISPR Therapeutics has found success in gene-editing cells so that the cells avoid such immune responses.Now the two companies are combining their respective technologies to develop a stem cell-based therapy that could effectively cure type 1 diabetes.According to the agreement announced Monday, CRISPR (NASDAQ: CRSP) is set to pay Sa...
Tags: Deals, Startups, Cancer, Trends, Diabetes, San Diego, Biotech, Life Sciences, CRISPR Therapeutics, Type 1 Diabetes, National blog main, Boston blog main, San Diego blog main, San Diego top stories, CRISPR-Cas9, Viacyte


Biotech Roundup: ASCO Ahead, CAMP4’s Cash, Ambien Tweeting & More

For the next five days, the oncology community’s attention will focus on Chicago. The Windy City is the home for the American Society of Clinical Oncology’s annual meeting, and it kicks off today. Many ASCO attendees will zero in on potential cancer drug combinations. They’re seen as the key to expanding the reach of caner immunotherapy, which still works on just a small fraction of patients. Among other news, expect a post-mortem analysis of a once-promising immunotherapy combination tha...
Tags: Deals, Startups, Cancer, Trends, Investing, Food And Drug Administration, Fda, National, Biotech, Roseanne Barr, Medicaid, Life Sciences, Clinical Trials, ASCO, American Society of Clinical Oncology, Roche


FDA Halts One of the First Human CRISPR Studies Before it Begins

A trial planning to use the gene-editing tool CRISPR on sickle cell patients has been put on hold due to unspecified questions from US regulators. From a report: CRISPR Therapeutics, which is developing the therapy, sought approval from the US Food and Drug Administration in April to begin the study. The therapy involves extracting stem cells from a patient's bone marrow and editing them with CRISPR in the lab. Once infused back into the patient, the idea is that the edited cells would give rise...
Tags: US, Tech, Fda, US Food and Drug Administration, CRISPR Therapeutics


NEA promotes two to GP

New Enterprise Associates Inc has promoted Carmen Chang and Dr. Ali Behbahani to general partner. Chang joined NEA in 2012 while Behbahani came on board in 2007. PRESS RELEASE MENLO PARK, Calif., May 23, 2018 /PRNewswire/ — New Enterprise Associates, Inc. (NEA) today announced that two members of its investing team have been promoted to General Partner: Carmen Chang, a technology investor and Chairman and Head of the firm’s Asia practice, and Ali Behbahani, M.D., a healthcare investor focused on...
Tags: Asia, China, Trends, People, Ali, Stanford University, Nea, Carmen, Lehman Brothers, Chang, CRISPR Therapeutics, SMIC, Stanford Law School, Menlo Park Calif, New Enterprise Associates Inc, Scott Sandell


Gene therapy treatment for blood disease approved in Europe

Genetically modification of humans has been been approved for the first time in Europe. Swiss-based biotech company Crispr Therapeutics hope to find a way of curing blood disease beta thalassaemia.... [[ This is a content summary only. Visit my website for full links, other content, and more! ]]
Tags: Europe, Innovation, Gene, CRISPR Therapeutics


Breakthrough CRISPR Gene Editing Trial Set to Begin This Year

Biotech company CRISPR Therapeutics is set to treat Europe’s patients with the CRISPR gene-editing tool this year following regulatory approval for trials. Researchers will apply the much-hyped tool to patients with beta thalassaemia, an inherited blood disorder that affects the body’s production of hemoglobin—a protein red blood cells use to carry oxygen around the body—U.K.’s Telegraph newspaper reported. Beta thalassemia is relatively common worldwide, according to the U.S. National Library...
Tags: Europe, Science, CRISPR Therapeutics, U S National Library of Medicine, U K 's Telegraph


Bio Roundup: Trials to Watch, Mega Deals, Video Game Therapy & More

With 2018 around the corner, this was a week to look ahead. At Xconomy, we zeroed in on several clinical trials that could become major stories in the life sciences. Other healthcare milestones are on the way, too. The FDA will consider for the first time whether a video game should be approved as medicine. The agency could also give its first nod for a gene therapy. We could see the first clinical trial by a U.S. company for a CRISPR-Cas9 gene editing treatment. And, of course, there are...
Tags: Deals, Startups, Boston, Trends, Vc, Lung Cancer, Alzheimer's Disease, Fda, National, Life Sciences, Jennifer Miller, Major Depressive Disorder, Clinical Trials, Roche, Gilead Sciences, UnitedHealth Group


Bio Roundup: Nobel Pursuit, Fundraising Fruit, A Rhythmic IPO & More

The 2017 Nobel Prizes with a biomedical bent were announced this week. Three researchers shared the physiology and medicine prize for their work shining light on the circadian rhythms that govern the wake-and-sleep cycles of all organisms. That basic research is working its way into applications such as drugs that help regulate our body clocks. Another academic trio won the chemistry Nobel for cool—very, very cool—electron microscopy. Their work has led to microscopic images of living mol...
Tags: Deals, Ipo, Trends, Ceo, Ulcerative Colitis, Chemistry, Fundraising, Venture Capital, Peter Thiel, M&a, Deal, Circadian Rhythms, National, Biotech, Donald Trump, Partnership


KSQ Bets on CRISPR-Juiced Drug Discovery With $76M & Ex-Genzyme CEO

CRISPR-Cas9 makes headlines as a gene editing tool for potential therapies, but pharma and biotech are also using it to as a tool to discover new drugs. A high-powered startup, KSQ Therapeutics, is the latest firm to join their ranks. Flagship Pioneering has been incubating the Cambridge, MA, company since 2015. KSQ has closed a $76 million financing and hired former top Sanofi Genzyme executive David Meeker—who left the company in April—as its CEO. Like another startup Flagship unveiled ...
Tags: Deals, Startups, Boston, Trends, Vc, Biotech, Life Sciences, Polaris Partners, Editas Medicine, UCSF, CRISPR Therapeutics, ARCH Venture Partners, Gene Editing, Cambridge MA, Intellia Therapeutics, National blog main


How Bayer and Ginkgo Teamed Up in a $100M Synthetic Biology Bet

Nitrogen is essential for plant growth and photosynthesis, but plants can’t pull it directly from air. They rely on bacteria on their roots to convert the gas into a usable form. Many major food crops don’t have these bacteria but Bayer wants to change that. The multinational company is teaming up with Boston startup Ginkgo Bioworks to form a new company, placing a big bet on technology to engineer new microorganisms that could bring nitrogen fixation to more crops, and reduce the amount ...
Tags: Startups, Boston, Trends, It, Monsanto, Cargill, Biotech, Novozymes, Synthetic Biology, Ginkgo Bioworks, Indigo, Life Sciences, Bayer, North Carolina State University, Archer Daniels Midland, CRISPR Therapeutics


Homology Med Bags $83.5M More, Fueling Push For Gene Editing Twist

One day after the release of a Nature Medicine paper warning of the potential hazards of testing CRISPR-Cas9 gene editing in humans, Homology Medicines, a startup advancing a different genetic surgery technique, has just grabbed a big round of funding to make its own clinical push. Homology, of Bedford, MA, wrapped up an $83.5 million Series B round this morning. A wide group of investors led by Deerfield Management provided the funding, bringing the company’s total amount raised to a who...
Tags: Deals, Startups, Boston, Dna, Trends, Vc, Novartis, Shire, Cystic Fibrosis, Temasek, Life Sciences, Editas Medicine, Clinical Trials, CRISPR Therapeutics, ARCH Venture Partners, David Scott


China sides with Emmanulle Charpentier and Jennifer Doudna in CRISPR patent war

 Continuing the patent dispute internationally, China has now given the Charpentier/Doudna side a patent to edit genes in the country. CRISPR pioneers Emmanuelle Charpentier and Jennifer Doudna lost a patent case to the Broad Insititute earlier this year when the court determined the Broad Insititute had an application markedly different than Charpentier’s and Doudna’s overall patent. Read More
Tags: China, Tech, Bio, Patent, Patent Infringement, Jennifer Doudna, CRISPR Therapeutics, Emmanuelle Charpentier, Charpentier, Doudna, Emmanulle Charpentier, Charpentier Doudna, Broad Insititute


Bio Roundup: ASCO Combo Frenzy, Maine’s Free DNA Tests, Sema4 & More

Over the next four days, the Second City will be the center of the biomedical world. The American Society of Clinical Oncology’s annual meeting in Chicago brings together thousands of researchers from across the globe to discuss the latest progress in the war against cancer. On tap this year: the crush of immunotherapy drug combinations, the latest in cell therapy, advances in targeted cancer drugs and much more. Xconomy has some prep work to get you ready for ASCO below, along with all t...
Tags: Deals, Cancer, Trends, Merck, Chicago, Maine, National, Allergan, Immunotherapy, Second City, Roundups, Life Sciences, Polaris Partners, Editas Medicine, Migraine, Amgen


First Trial in Sight, Editas Cuts $90M Eye Drug Deal With Allergan

Slowly but surely, CRISPR-Cas9 gene editing treatments are working their way towards human clinical testing, spurring more large pharmaceutical companies to get in on their future. The latest today is Allergan, which has just aligned itself with Editas Medicine on treatments for a group of genetic eye diseases. Allergan (NYSE: AGN) will pay Cambridge, MA-based Editas (NASDAQ: EDIT) $90 million in cash up front to get an option to license up to five experimental gene editing treatments for...
Tags: Deals, Drugs, Boston, Trends, Novartis, Allergan, Berkeley, University Of California, Cystic Fibrosis, Life Sciences, Bayer, Editas Medicine, Clinical Trials, CRISPR Therapeutics, Gene Editing, Cambridge MA


Vertex Bags Concert’s Rival CF Drug For $160M, Plans Combo Studies

Concert Pharmaceuticals has been plugging away with an experimental cystic fibrosis drug that, if successful, might someday pose a threat to Vertex Pharmaceuticals. So rather than wait to find out, Vertex today paid $160 million in cash, up front, to bring the drug in house. Boston-based Vertex (NASDAQ: [[tickerVRTX]]) has acquired CTP-656, a CF drug currently in Phase 2 testing, from Concert (NASDAQ: CNCE). Vertex could pay Concert, of Lexington, MA, another $90 million in downstream pay...
Tags: Deals, Drugs, Boston, Trends, Abbvie, Cystic Fibrosis, Life Sciences, Clinical Trials, CRISPR Therapeutics, Vertex, CTP, Hepatitis C, Kalydeco, Concert Pharmaceuticals, Moderna Therapeutics, Vertex Pharmaceuticals


Versant Closes on $400M Fund, Eyes More Biotech Deals in Europe

Versant Ventures now has $400 million in its coffers to fuel its pursuit of early-stage healthcare technologies and startups, and it has a particular goal of expanding its investment approach in Europe. With the closing of its sixth fund announced Tuesday, San Francisco-based Versant now aims to invest in as many as 25 companies in both North America and Europe—half of those investments in “companies we create from scratch,” says Brad Bolzon, Versant’s managing director. Those companies w...
Tags: Startups, Europe, San Francisco, Trends, Investing, Venture Capital, Biotech, North America, Stanford University, Life Sciences, Bayer, Celgene, CRISPR Therapeutics, Versant, Versant Ventures, National blog main


VC-backed Crispr Therapeutics raises $56 mln for IPO

Crispr Therapeutics, a provider of gene-editing technology, has debuted its IPO after pricing its 4 million shares at $14 per share. The stock began trading October 19, 2016 on the NASDAQ under the ticker symbol “CRSP.” Citigroup, Piper Jaffrey and Barclays are serving as the lead underwriters. Crispr’s backers included Franklin Templeton Investments, New Leaf Venture Partners, Clough Capital Partners LP and Wellington Capital Management LLP. PRESS RELEASE BASEL, Switzerland and CAMBRIDGE, Mass....
Tags: Minneapolis, Trends, IPOs, Barclays, Crispr, Securities And Exchange Commission, Basel Switzerland, CRISPR Therapeutics, Barclays Capital Inc, Citigroup Global Markets Inc, Nasdaq Global Market, Guggenheim Securities, Broadridge Financial Solutions


Bio Roundup: Bristol & Illumina Blues, Sickle Cell News & More

On Aug. 4, shares of Bristol-Myers Squibb closed at $75.32. Today, shares are worth just over $50. That means in three months, Bristol has lost a third of its value, equivalent to about $40 billion in market capitalization. The reason? One failed clinical trial has left rival Merck in the lead position to have what could be part of the new standard of care for lung cancer. That story and plenty more in this week’s roundup. TOP STORIES —The European Society of Medical Oncology held its annua...
Tags: Deals, Europe, Japan, New York, Drugs, Singapore, Cancer, Trends, Merck, IPOs, Brooklyn, Cambridge, San Diego, National, Bristol, Immunotherapy


CRISPR loses Nobel to tiny machines

 CRISPR, the gene-editing technology revolutionizing the biotech industry, has failed to take home the Nobel prize in chemistry for the second year in a row. Instead, the award went to Jean-Pierre Sauvage, J. Fraser Stoddart, and Bernard L. Feringa – three men who developed the world’s smallest machines using molecular physics. Each will share equally in the 8 million Swedish kronor,… Read More
Tags: Health, TC, Science, Biology, Drama, Tech, Mit, Harvard, Berkeley, Bio, Crispr, Editas Medicine, Enzymes, Jennifer Doudna, CRISPR Therapeutics, George Church


Biotech Roundup: CRISPR’s 3rd IPO, Gender Diversity, Buyouts & More

Across the nation, and even looking back into the past, health was in the headlines this week. Our presidential candidates were either recovering from pneumonia or talking up their health records. New documents came to light that showed the sugar industry paid for studies downplaying the ties between sugar and heart disease. And the drug-price frenzy continued, with Senators Tammy Baldwin and John McCain introducing a new bill to combat price hikes and Mylan CEO Heather Bresch set to testif...
Tags: Google, Deals, Startups, Sofinnova Partners, Boston, Trends, IPOs, Mit, Vc, Diabetes, Cambridge, Switzerland, Dallas, Capitol Hill, Fda, National


Seeking to Join Editas, Intellia, CRISPR Tx Makes Long Awaited IPO Push

Investors hoping to buy into the vast, yet still unproven drugmaking potential of the gene editing system CRISPR-Cas9 will soon have three different companies to choose from. CRISPR Therapeutics filed for an IPO on Friday, meaning it could soon join Boston-area rivals Editas Medicine and Intellia Therapeutics in the expanding club of publicly traded CRISPR-Cas9 drug developers. Basel, Switzerland- and Cambridge, MA-based CRISPR has been slowly amassing rounds of venture funding, adding part...
Tags: Startups, Ipo, Boston, Trends, IPOs, Cambridge, Fda, Novartis, Cystic Fibrosis, Crispr, New Enterprise Associates, Life Sciences, Bayer, Flagship Ventures, Polaris Partners, Editas Medicine


Biotech Roundup: CRISPR’s 1st Trial, IPO Insiders, Zika & More

There was some history made this week, and not just in Cleveland, where LeBron James & co. capped off a historic comeback to bring the city its first sports title in over 50 years. Plans were revealed for the first-ever human clinical trial of CRISPR-Cas9, the gene editing system that has been taking the scientific world by storm over the past few years. The FDA still has to clear the study, but if it does, it’s sure to become one of the most closely watched scientific events in more than a...
Tags: Deals, Startups, Ebola, Sweden, Senate, White House, Ipo, San Francisco, Trends, Vc, Harvard University, House, Cambridge, Affordable Care Act, Medicare, Ibm


Crispr Therapeutics raises $38 mln

Crispr Therapeutics said June 24 that it raised another $38 million in Series B financing, which closes the round at nearly $140 million. Participating investors in this round include Franklin Templeton Investments, New Leaf Venture Partners, funds advised by Clough Capital Partners LP and Wellington Capital Management LLP, and other undisclosed funds specializing in life sciences. Crispr is a biopharmaceutical company. Source: Business Wire  
Tags: Trends, CRISPR Therapeutics, VC Deals, Clough Capital Partners LP